AndroGel Regulatory Status: US, EU, Canada, and UK Approvals Explained

How AndroGel Works: Mechanism of Action

Testosterone gel delivers exogenous testosterone through the skin into systemic circulation, restoring serum concentrations in men whose testes or hypothalamic-pituitary axis cannot maintain normal production. The hydroalcoholic vehicle evaporates on application, leaving testosterone to absorb through the stratum corneum over several hours. Approximately 10% of the applied dose reaches the bloodstream, producing steady-state levels within 24 to 48 hours of daily use 1.

Once absorbed, testosterone binds to androgen receptors in skeletal muscle, bone, adipose tissue, and the central nervous system. It also undergoes 5-alpha reduction to dihydrotestosterone (DHT) in target tissues and aromatization to estradiol in adipose tissue. The Testosterone Trials (TTestosterone Trials, N=790 men aged 65 and older with serum testosterone <275 ng/dL) confirmed that daily application of 1% testosterone gel raised mean serum testosterone from 232 ng/dL to 469 ng/dL (mid-normal range) over 12 months 2. Downstream clinical effects included improved sexual function (measured by the Psychosexual Daily Questionnaire, P<0.001 vs. placebo), modest gains in 6-minute walk distance (P=0.04), and increased volumetric bone mineral density at the spine by 7.5% over 12 months 2.

The gel formulation avoids the supraphysiologic peaks seen with intramuscular injections. That pharmacokinetic profile matters. The Endocrine Society's 2018 guideline notes that transdermal testosterone "provides physiologic testosterone levels and avoids the peaks and troughs associated with injectable formulations" 3.

United States: FDA Approval and Controlled Substance Classification

AndroGel 1% (testosterone gel, 50 mg per 5 g packet) received FDA approval on February 28, 2000, under NDA 21-015, sponsored by Unimed Pharmaceuticals (later acquired by Solvay, then AbbVie) 4. A higher-concentration formulation, AndroGel 1.62%, was approved in April 2011 under NDA 22-309, designed to reduce application volume while delivering equivalent testosterone exposure 5.

The approved indication is narrow: replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The FDA label explicitly states the drug is not approved for age-related testosterone decline or for use in women.

Testosterone is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act of 1990. Prescribers must follow DEA record-keeping requirements, and pharmacies must treat it with the same dispensing controls applied to other Schedule III drugs. Refill limits (up to five refills within six months) and state-level prescription monitoring programs add further regulatory layers.

In March 2015, the FDA issued a safety communication requiring all testosterone products to carry updated labeling about possible increased cardiovascular risk 6. The agency also restricted the indication language, clarifying that testosterone products are approved only for men with low testosterone caused by specific medical conditions (e.g., Klinefelter syndrome, pituitary disorders, chemotherapy), not for low levels related to aging alone.

Generic testosterone gel 1% entered the US market in 2015 after Perrigo and Teva received ANDA approvals. AbbVie's branded AndroGel revenue dropped from approximately $1.2 billion in 2014 to $530 million by 2017, reflecting rapid generic substitution.

European Union: Testogel and the Decentralized Procedure

In Europe, testosterone gel is marketed primarily as Testogel (Besins Healthcare) and was authorized through the EU's decentralized procedure, with France as the reference member state. The 16.2 mg/g gel formulation (equivalent to the US 1.62% product) holds marketing authorizations across France, Germany, Spain, Italy, the Netherlands, and more than 20 additional member states 7.

The European Medicines Agency (EMA) classifies testosterone as a prescription-only medicine. EU prescribing is governed by each member state's national competent authority, but the indication language is consistent: testosterone replacement therapy for male hypogonadism "when testosterone deficiency has been confirmed by clinical features and biochemical tests" 8.

The European Association of Urology (EAU) 2024 guideline on male hypogonadism states that "a serum total testosterone level below 12 nmol/L (346 ng/dL), measured on at least two occasions in the morning, is required before initiating testosterone replacement therapy" 8. This two-measurement threshold adds a layer of diagnostic rigor that goes beyond many US clinical practices.

In 2014, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed cardiovascular risk data for all testosterone-containing medicines and concluded that the evidence did not confirm an increased risk of heart problems but recommended that product information be updated to reflect the known risk of polycythemia 9. This diverged from the FDA's approach, which emphasized cardiovascular labeling.

EU member states also regulate secondary transfer risk. All Testogel labels include warnings about skin-to-skin testosterone transfer to women and children, requiring patients to cover the application site with clothing after the gel dries and to wash the area before close physical contact.

Canada: Health Canada Approval and Provincial Formulary Access

Health Canada approved testosterone gel 1% (marketed as AndroGel by AbbVie Canada) for male hypogonadism in 2001. The product holds a Drug Identification Number (DIN) and is classified as a Schedule IV controlled substance under Canada's Controlled Drugs and Substances Act. Unlike the US Schedule III classification, Canada's Schedule IV imposes less restrictive dispensing requirements but still mandates prescription-only access 10.

Provincial formulary coverage varies considerably. Ontario's Ontario Drug Benefit program lists testosterone gel as a Limited Use benefit (LU code 427), requiring documentation of two morning serum testosterone measurements below 7.0 nmol/L and a confirmed organic cause of hypogonadism. Alberta's drug benefit list applies similar diagnostic requirements. British Columbia's PharmaCare does not routinely cover testosterone gel, shifting cost to private insurers or patients 10.

In 2014, Health Canada issued a safety review aligning with the FDA's cardiovascular concern, adding label warnings about the potential for serious cardiovascular events including myocardial infarction and stroke. The Canadian Urological Association's 2021 guideline recommends that "all men receiving testosterone therapy should be counselled about the uncertain cardiovascular risk and monitored with hematocrit levels every 6 to 12 months" 11.

Generic testosterone gel became available in Canada following patent expiration. Taro Pharmaceutical and other manufacturers now supply lower-cost alternatives, though brand-name AndroGel retains market share in patients stabilized on the original formulation.

United Kingdom: MHRA Authorization and NHS Prescribing

In the United Kingdom, testosterone gel is available under two primary brand names: Testogel (Besins Healthcare) and Tostran (Kyowa Kirin). Both hold Marketing Authorizations from the Medicines and Healthcare products Regulatory Agency (MHRA) as prescription-only medicines (POM). Testogel 16.2 mg/g gel was first authorized in the UK in 2003 12.

The UK followed the EMA's regulatory framework until Brexit. Since January 1, 2021, the MHRA operates as an independent regulator, though it has retained the EMA's existing marketing authorizations through the "grandfathering" provisions of the Northern Ireland Protocol and the Medicines and Medical Devices Act 2021.

The British Society for Sexual Medicine (BSSM) published updated guidelines in 2017, recommending testosterone replacement "only after two separate early-morning fasting testosterone measurements confirm a total testosterone below 12 nmol/L, or a free testosterone below 0.225 nmol/L" 12. The BSSM guideline also specifies that testosterone therapy should be initiated only by clinicians with expertise in male hormone management, a recommendation that has led many NHS Clinical Commissioning Groups (now Integrated Care Boards) to restrict initiation to secondary care endocrinologists or urologists.

NHS prescribing data from 2023 shows that Testogel and Tostran together accounted for over 380,000 NHS prescriptions annually in England, with a combined net ingredient cost exceeding £32 million 12. Testosterone gel represents the most commonly prescribed testosterone formulation in UK clinical practice, outpacing intramuscular injections (Sustanon 250, Nebido) in prescription volume.

Private clinics in the UK, particularly those operating in the men's health and hormone optimization space, prescribe testosterone gel more liberally than the NHS pathway permits. The MHRA has issued periodic warnings about online clinics prescribing testosterone without adequate diagnostic workup.

Comparative Regulatory Overview: Key Differences Across Regions

The four regulatory regions share the same core requirement: a confirmed diagnosis of hypogonadism before prescribing. The differences lie in diagnostic thresholds, controlled substance classification, and post-market safety messaging.

The US applies the strictest controlled substance scheduling (Schedule III), while Canada uses Schedule IV and the EU/UK do not schedule testosterone under narcotics legislation at all (though it remains prescription-only). The diagnostic testosterone threshold also varies: most US guidelines use 300 ng/dL (10.4 nmol/L) as the lower limit of normal, while European and UK guidelines use 12 nmol/L (346 ng/dL), a slightly higher cutoff that could exclude some borderline patients from treatment 3.

Cardiovascular labeling diverges meaningfully. The FDA mandated a prominent cardiovascular warning in 2015, driven partly by the TTrials cardiovascular sub-study and observational data. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, subsequently showed that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo (hazard ratio 0.96; 95% CI, 0.78 to 1.17) over a mean follow-up of 33 months 13. This finding may eventually prompt regulatory reconsideration of the cardiovascular warning language across all four regions.

The EMA has not matched the FDA's cardiovascular warning intensity, instead focusing post-market attention on polycythemia risk. Health Canada and the MHRA have adopted middle-ground positions, acknowledging cardiovascular uncertainty while stopping short of the FDA's explicit caution.

Generic availability has reduced costs most dramatically in the US market, where multiple ANDA-approved generics compete. The UK's NHS prescribing prices for Testogel remain regulated through the Drug Tariff. Canada and the EU fall between these poles, with generic entry proceeding at different rates across provinces and member states.

Safety Monitoring Requirements Across All Jurisdictions

Every regulatory authority requires the same core monitoring panel for patients on testosterone gel. Hematocrit must be checked at baseline, at 3 to 6 months, and then annually; treatment should be withheld if hematocrit exceeds 54% 3. Prostate-specific antigen (PSA) and digital rectal examination are recommended at baseline and at 3 to 12 months, depending on the guideline. Lipid panels, liver function tests, and bone density assessments round out the recommended surveillance.

The Endocrine Society guideline recommends against testosterone therapy in men with "breast or prostate cancer, a palpable prostate nodule or induration, PSA above 4 ng/mL, hematocrit above 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, or desire for fertility" 3. These contraindications are consistent across all four regulatory environments, though specific PSA thresholds may vary by local practice.

Transfer risk remains a unique concern for gel formulations. All four regulatory authorities mandate patient counseling on avoiding skin-to-skin contact with women and children at the application site. The FDA issued a black box warning in 2009 after reports of virilization in children exposed to testosterone gel through secondary transfer, including cases of premature pubic hair development and genital enlargement in toddlers 4.

Men seeking fertility preservation should not use testosterone gel in any jurisdiction. Exogenous testosterone suppresses gonadotropin secretion, which reduces intratesticular testosterone and impairs spermatogenesis. Recovery of sperm production after discontinuation typically requires 6 to 12 months but may be incomplete in some patients 3.